Compare Enveric Biosciences Inc (ENVB) vs iShares Core S&P 500 ETF (IVV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs iShares Core S&P 500 ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while iShares Core S&P 500 ETF trades at $780.57 (market cap $899.63B). The key difference: iShares Core S&P 500 ETF is far larger — about 132298.5× Enveric Biosciences Inc's market cap, and iShares Core S&P 500 ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and iShares Core S&P 500 ETF for 46 Days on average.
| ENVB | IVV | |
|---|---|---|
Market Cap | $6.80M | $899.63B |
Volume | 64,867 | 3,643,926 |
Sector | Health | Broad Market / Factor |
52-Week High | $10.80 | $782.58 |
52-Week Low | $1.27 | $634.93 |
Typical Hold Time | 14 Days | 46 Days |
Enterprise Value | -$1.49M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
IVV, tracking the S&P 500, trades at $780.60, down 0.25% on the day. Technical indicators show a bullish trend with moving averages strongly positive, though RSI suggests potential overbought conditions near-term. The ETF remains a core holding for broad US equity exposure, with recent news highlighting strong corporate earnings growth expectations of 35% for 2026. Market sentiment is mixed as valuations attract scrutiny despite index strength.
Outlook remains constructive given the S&P 500's earnings momentum and historical seasonal trends favoring year-end rallies. Key risks include potential profit growth deceleration to 15% in 2027 and concentration in top holdings. The ETF offers diversified exposure to large-cap US equities, with the current level near pivot point support providing a strategic entry zone for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →
